First Tracks Biotherapeutics Inc
NASDAQ:TRAXBiotechnology
-$0.89 today
- Market cap
- $1.87B
- Beta
- 0.00
- P/E (TTM)
- -6.1
- EPS (TTM)
- -$2.81
Volume 0.75M
Average 0.43M
Balance Sheet
Inspect the capital base behind the business.
Assets
$330.55M
FY 2025 · Annual
-25.2% YoYLiabilities
$43.05M
FY 2025 · Annual
-14.4% YoYEquity
$287.49M
FY 2025 · Annual
-26.6% YoYBalance Sheet
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $248.5M |
| Short-term Investments | $38.0M |
| Other Current | $2.9M |
| Total Current Assets | $289.4M |
| PP&E (Net) | $1.2M |
| Total Non-current Assets | $1.2M |
| Total Assets | $290.6M |
Analysis
Selected assets total $290.6M for Latest. The largest visible component is Cash & Equivalents at $248.5M, about 85.5% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 12, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 6, 2026 | |
| 424B3 | 424B3 filing | Nov 4, 2026 | |
| 424B3 | 424B3 filing | Nov 4, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 3, 2026 |
How much cash does TRAX have?
First Tracks Biotherapeutics Inc (TRAX) reported $238.20M in cash and equivalents in fiscal 2025.
How much debt does TRAX carry?
First Tracks Biotherapeutics Inc (TRAX) reported $14.11M of total debt, with net debt of -$224.08M.
Continue the stock analysis
Jump to another research area for this company.